2015). It has been reported that multiple pathogens can activate intracellular signalling transduction pathways, such as the ERK1/2 signalling pathway, leading to a series of biological reactions participating in cardiac hypertrophy (Bernardo et al. 2010). Several medications including angiotensin converting enzyme inhibitors (ACEI) and calcium channel blockers (CCBs) have been used clinically. However, the high mortality rate of patients necessitates more effective therapeutic and protective medications (Tham et al. 2015). The gene discussed is MAPK3; the disease is cardiac hypertrophy.